Chelohart
/ Khavinson-tradition cardiac muscle bioregulator (variant)ALIAS · Chelohart · Cardiac peptide variant
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Chelohart is one of several Khavinson-tradition cardiac-targeted bioregulator preparations marketed by Russian gerontology suppliers. Indexed PubMed primary literature isolating chelohart as the studied agent is not identifiable.
Chelohart is presented within the Khavinson peptide-bioregulator framework as a cardiac-muscle preparation. The class-level hypothesis is sequence-specific tissue-targeting via short-peptide DNA binding and transcriptional modulation. Chelohart-specific mechanistic characterisation is absent from indexed primary literature.
Tier 4. No peptide-specific clinical or preclinical study with chelohart as the named agent in indexed PubMed literature. No replicated independent evidence base.
No formal human safety database. No peptide-specific safety record.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication. Chelohart has no replicated independent evidence base, and the cardiac-targeting claim sits on a class hypothesis rather than peptide-specific studies. Vendor sales presume bioactivity that the published record does not establish, and the specific molecular sequence sold under this name is not externally verifiable.